<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AM03" />
<ATC code="J04AC01" />
<ATC code="J04AC51" />
<ATC code="J04AM02" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
<ATC code="J04AM01" />
<ATC code="J04AM04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
